| Date | Time | Source | Headline | Symbol | Company |
| 03/08/2024 | 4:17PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 03/08/2024 | 4:16PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/29/2024 | 4:12PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/29/2024 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/28/2024 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/14/2024 | 4:00PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/13/2024 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/12/2024 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/08/2024 | 5:20PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/08/2024 | 4:49PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/08/2024 | 1:22AM | GlobeNewswire Inc. | Sana Biotechnology Announces Pricing of Upsized Public Offering | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/07/2024 | 9:59PM | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/07/2024 | 5:05PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/07/2024 | 4:12PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/07/2024 | 4:01PM | GlobeNewswire Inc. | Sana Biotechnology Announces Proposed Public Offering of Common Stock | NASDAQ:SANA | Sana Biotechnology Inc |
| 01/09/2024 | 9:00AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 01/05/2024 | 9:00AM | GlobeNewswire Inc. | Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies | NASDAQ:SANA | Sana Biotechnology Inc |
| 01/03/2024 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/18/2023 | 4:51PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/15/2023 | 4:34PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/11/2023 | 4:01PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/11/2023 | 9:00AM | GlobeNewswire Inc. | Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/01/2023 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/27/2023 | 7:01PM | PR Newswire (US) | Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/21/2023 | 9:00AM | GlobeNewswire Inc. | Sana Biotechnology to Present at November and December 2023 Investor Conferences | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/21/2023 | 6:00AM | PR Newswire (US) | Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/17/2023 | 9:00AM | GlobeNewswire Inc. | Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/09/2023 | 4:05PM | GlobeNewswire Inc. | Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/08/2023 | 4:24PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/08/2023 | 4:14PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |